This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- CM-4307
- DrugBank Accession Number
- DB15414
- Background
CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 467.85
Monoisotopic: 467.1051328 - Chemical Formula
- C21H16ClF3N4O3
- Synonyms
- DONAFENIB
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 41XGO0VS1U
- CAS number
- 1130115-44-4
- InChI Key
- MLDQJTXFUGDVEO-FIBGUPNXSA-N
- InChI
- InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3
- IUPAC Name
- 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-(2H3)methylpyridine-2-carboxamide
- SMILES
- [2H]C([2H])([2H])NC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
References
- General References
- Not Available
- External Links
- ChemSpider
- 23937167
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Treatment Chemotherapy Effects / HCC 1 3 Completed Treatment Metastatic Colorectal Cancer (CRC) 1 3 Terminated Treatment Differentiated Thyroid Cancer (DTC) 1 2 Completed Treatment Differentiated Thyroid Cancer (DTC) 1 2 Enrolling by Invitation Treatment Adenocarcinoma of the Biliary Tract 1 2 Not Yet Recruiting Prevention Antimetabolites / Antineoplastic Agents / Carcinoma / Donafenib / Fluorouracil / Hepatocellular Carcinoma / Neoplasms, Gastrointestinal / Neoplasms, Hepatic / Oxaliplatin 1 2 Not Yet Recruiting Treatment Hepatocellular Carcinoma 5 2 Not Yet Recruiting Treatment Pancreatic Metastatic Cancer 1 2 Not Yet Recruiting Treatment Unresectable Hepatocellular Carcinoma (HCC) 1 2 Recruiting Treatment Anesthetics Adverse Reaction / Chemotherapy / Metastatic Cervical Carcinoma / Persistent Advanced Cervical Carcinoma / Recurrent Cervical Carcinoma / Survival Outcomes / Targeted Therapy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00171 mg/mL ALOGPS logP 4.12 ALOGPS logP 4.34 Chemaxon logS -5.4 ALOGPS pKa (Strongest Acidic) 11.55 Chemaxon pKa (Strongest Basic) 3.03 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 92.35 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 114.52 m3·mol-1 Chemaxon Polarizability 41.23 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 15:27 / Updated at June 12, 2020 16:53